

October 14, 2015

BIONIK

Bionik Laboratories to Present at the 14th Annual BIO Investor Forum on October 21, 2015

- Presentation with live webcast on Wednesday, October 21st at 3:00 p.m. PDT -

TORONTO, Oct. 14, 2015 /PRNewswire/ --[Bionik Laboratories Corp.](#) (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), announced today that it will present at the [14th Annual BIO Investor Forum](#) being held October 20-21, 2015 at the Parc 55 in San Francisco, California.



BIONIK
LABORATORIES

Peter Bloch, CEO of Bionik, will present a corporate overview on Wednesday, October 21, 2015 at 3:00 p.m. PDT. As part of his presentation he will review the Company's plans for the clinical development and commercial deployment of its primary product [ARKE™](#), a proprietary lower-body exoskeleton robotic device that is designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Mr. Bloch will also discuss Bionik's near-term strategy to expand and develop a robust product portfolio both internally and by acquiring or licensing synergistic products and

technologies.

A live webcast of the presentation will be available on Bionik's [IR Calendar](#) in the [Investor Relations](#) section of the Company's website (www.bioniklabs.com). A webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

About BIO

[BIO](#) is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14th Annual [BIO Investor Forum](#) is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the [BIO International Convention](#), the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About Bionik Laboratories

Bionik Laboratories (OTCQX: BNKL) is a medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that allows paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US\$13.1 million which enables the company to rapidly advance its development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional

financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

Logo - <https://photos.prnewswire.com/prnh/20150817/258751LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/bionik-laboratories-to-present-at-the-14th-annual-bio-investor-forum-on-october-21-2015-300159175.html>

SOURCE Bionik Laboratories Corp.